This conversion is generally pro-tumorigenic, except that in AML and glioma cells this oncometabolite inhibits FTO enzymatic activity and m6A accumulation on FTO targets, thus eliciting tumor suppressing effects in vitro and in vivo [57]. The gene discussed is FTO; the disease is central nervous system cancer.